The Linear No-Threshold Theory of Radiation Carcinogenesis should be Rejected. The Linear No-Threshold Theory of Radiation Carcinogenesis should be Rejected.

The Linear No-Threshold Theory of Radiation Carcinogenesis should be Rejected‪.‬

Journal of American Physicians and Surgeons 2008, Fall, 13, 3

    • $5.99
    • $5.99

Publisher Description

It is commonly stated that "any radiation dose, no matter how small, can cause cancer." The basis for that statement is the linear-no threshold theory (LNT)--which might more appropriately be called "linear-no threshold hypothesis"--of radiation carcinogenesis. According to LNT, if a 1 Gy (100 rad) dose gives a cancer risk R, the risk from a dose of 0.01 Gy (1 rad) is R/ 100, the risk from 0.00001 Gy (1 millirad) is R/100,000, and so on. Thus the cancer risk is not zero regardless of how small the dose. However, over the past several years, many radiation health scientists have come to regard risk estimates in the low-dose region based on LNT as exaggerated or completely negligible. For example, the 6,000-member Health Physics Society, the principal organization for radiation protection scientists, issued a position paper (1) stating: "Below 10 rad... risks of health effects are either too small to be observed or are nonexistent." A similar position statement was issued by the American Nuclear Society. When the Health Physics Society Newsletter asked for submission of comments on validity of LNT, there were about 20 negative comments submitted and only a single comment supportive of LNT. In a worldwide poll conducted by the principal on-line discussion group of radiation protection professionals (RADSAFE), the vote was 118 to 12 against LNT. A 2001 Report by the French Academy of Medicine concluded that LNT is "without any scientific validity," and an elaborate joint study by the French Academy of Medicine and the French Academy of Sciences (2) strongly condemned the use of LNT.

GENRE
Business & Personal Finance
RELEASED
2008
22 September
LANGUAGE
EN
English
LENGTH
30
Pages
PUBLISHER
Association of American Physicians and Surgeons, Inc.
SELLER
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
297
KB
Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer
2010
Radiophobia Radiophobia
2022
Carcinogenicity Carcinogenicity
2021
Circulating Cell-Free DNA in Plasma/Serum of Lung Cancer Patients As a Potential Screening and Prognostic Tool (Clinical Report) Circulating Cell-Free DNA in Plasma/Serum of Lung Cancer Patients As a Potential Screening and Prognostic Tool (Clinical Report)
2006
Novel Therapies in Head and Neck Cancer: Beyond the Horizon Novel Therapies in Head and Neck Cancer: Beyond the Horizon
2020
Radioactive Clouds of Death Over Utah Radioactive Clouds of Death Over Utah
2013
Conviction Without a Crime: A True Story (Viewpoint Essay) Conviction Without a Crime: A True Story (Viewpoint Essay)
2008
Selective Serotonin: Reuptake Inhibitor (SSRI) Drugs: More Risks Than Benefits?(Report) Selective Serotonin: Reuptake Inhibitor (SSRI) Drugs: More Risks Than Benefits?(Report)
2009
Point/Counterpoint: The Case Against Bioidentical Hormones (Drug Overview) Point/Counterpoint: The Case Against Bioidentical Hormones (Drug Overview)
2008
The Failure of Vytorin and Statins to Improve Cardiovascular Health: Bad Cholesterol Or Bad Theory? The Failure of Vytorin and Statins to Improve Cardiovascular Health: Bad Cholesterol Or Bad Theory?
2008
The Need for Clinical Judgment in the Diagnosis and Treatment of Lyme Disease (Report) The Need for Clinical Judgment in the Diagnosis and Treatment of Lyme Disease (Report)
2009
Tactics Characteristic of Sham Peer Review (Editorial) Tactics Characteristic of Sham Peer Review (Editorial)
2009